Search This Blog

Monday, September 12, 2022

Problems persist for kids exposed to cannabis in the womb

 Children who were exposed to cannabis in the womb continue to show elevated rates of symptoms of psychopathology (depression, anxiety and other psychiatric conditions), even as—at ages 11 and 12—they head toward adolescence, according to research from the Department of Psychological & Brain Sciences' BRAIN Lab, led by Ryan Bogdan, associate professor in Arts & Sciences at Washington University in St. Louis.

The findings, published Monday, Sept. 12, 2022 in the JAMA Pediatrics, is a follow-up to 2020 research from the Bogdan lab that revealed younger children who had been prenatally exposed to  were slightly more likely to have had sleep problems, lower birth weight and lower cognitive performance, among other things.

In both cases, the effect is strongest when looking at exposure to cannabis after the  is known. To determine whether or not these associations persisted as the children aged, David Baranger, a postdoctoral researcher in the BRAIN Lab, returned to the more than 10,500 children from the 2020 analysis. They averaged 10 years old in 2020.

The data on the children and their mothers came from the Adolescent Brain and Cognitive Development Study (ABCD Study), an ongoing study of nearly 12,000 children, beginning when they were 9-10 years old, and their parents or caregivers. The study began in 2016, when participants were enrolled at 22 sites across the United States.

This seemingly small change in age—from 10 to 12—is an important one. "During the first wave, they were just children. Now they're edging up on adolescence," Baranger said. "We know this is a period when a large proportion of mental health diagnoses occur."

An analysis of the more recent data showed no significant changes in the rate of  as the  aged; they remain at greater risk for clinical psychiatric disorders and problematic substance use as they enter the later adolescent years.

"Once they hit 14 or 15, we're expecting to see further increases in mental health disorders or other psychiatric conditions—increases that will continue into the kids' early 20s," Baranger said.

More information: David A. A. Baranger et al, Association of Mental Health Burden With Prenatal Cannabis Exposure From Childhood to Early Adolescence, JAMA Pediatrics (2022). DOI: 10.1001/jamapediatrics.2022.3191

https://medicalxpress.com/news/2022-09-problems-persist-kids-exposed-cannabis.html

Recommended blood sugar levels to avoid diabetes-related damage

 The levels of long-term blood sugar, HbA1c, can be used to accurately determine the risk of a person with type 1 diabetes developing eye- and kidney complications. A study from Linköping University, Sweden, has shown that this level should be lower than 53 mmol/mol (7%). The study has followed individuals for more than 30 years after the onset of type 1 diabetes, and the results have been published in Diabetes Care.

People with diabetes may experience damage to the small blood vessels in various organs. The reasons for this are unclear, but it has been known since the 1990s that good control of blood sugar levels reduces the risk of complications. It has, however, not been clear what level of long-term sugar, HbA1c, people with type 1 diabetes should have in order to avoid serious damage to blood vessels in the eyes and kidneys.

"Our study determines accurately the levels of long-term sugar that can avoid complications. This knowledge can increase a person's motivation to keep their blood sugar level under control," says Hans Arnqvist, professor emeritus at Linköping University and leader of the study.

Researchers in the current study, known as VISS (Vascular Diabetic Complications in Southeast Sweden), have followed all children and adults younger than 35 years who developed type 1 diabetes during the period 1983-1987, and who received care in the South-East Healthcare Region of Sweden. All 447 newly diagnosed persons in the region during this period were included in the study. The researchers have followed the patients' HbA1c values, which reflect their average blood sugar levels during a longer period. They have also monitored the development of eye- and kidney damage in these patients for a period of between 32 and 36 years after diagnosis.

The small blood vessels in the eye are particularly susceptible to damage in type 1 diabetes. Nearly all patients experience small haemorrhages in the eye that do not affect their vision. In some cases, new blood vessels develop in the retina. The latter is known as 'proliferative retinopathy', and can lead to blindness. Another effect of diabetes concerns the area known as the 'macula' of the retina, where high-focus vision is located. Damage here leads to blurred vision.

The kidneys are not as sensitive to high blood sugar levels as the eye, but the important small blood vessels here can also be damaged. One consequence of such damage is the excretion of blood proteins in the urine. Albumin is the protein with highest concentration in the blood, and when it is present in the urine the condition is known as 'albuminuria'. The damage to the kidneys eventually leads to impaired kidney function and, in serious cases, kidney failure. This is a fatal condition if untreated, and the patient must either undergo dialysis or receive a kidney transplant.

The blood sugar level in a healthy person is very closely controlled, with a maximum HbA1c level of 42 mmol/mol (6.0%).

"The results of our study show that people with type 1 diabetes for at least 32 years should keep their mean long-term sugar level below 53 mmol/mol (7.0%), if they are to completely avoid serious damage. The risk of eye- and kidney complications increases as the level increases. Our conclusions relate to avoiding complications arising from blood vessel damage. But if a patient has problems with low blood sugar, hypoglycaemia, it's not possible to control the blood sugar level so strictly," says Hans Arnqvist.

The target level for HbA1c that is suggested by the results of the VISS study agrees with the individual targets recommended by the American Diabetes Association. In Sweden, target levels are given for groups, rather than individuals.

The previous follow-up by the research group was conducted 20 years after the onset of disease. Now after 30 years, the results show that damage has arisen at lower blood sugar levels than was the case after 20 years. More patients have experienced damage, despite having blood sugar levels that are not higher than those they have previously had. In other words, it seems that the threshold for developing complications falls gradually with time. This means that the study does not allow any conclusions for the recommended blood sugar levels of people with type 1 diabetes longer than 30 years after diagnosis.

The VISS study has received funding from the Swedish Child Diabetes Foundation and the Foundation Funds of Region Östergötland.


Story Source:

Materials provided by Linköping University. Original written by Karin Söderlund Leifler. Note: Content may be edited for style and length.


Journal Reference:

  1. Hans J. Arnqvist, Malin C. Westerlund, Mats Fredrikson, Johnny Ludvigsson, Maria Nordwall. Impact of HbA1c Followed 32 Years From Diagnosis of Type 1 Diabetes on Development of Severe Retinopathy and Nephropathy: The VISS StudyDiabetes Care, 2022; DOI: 10.2337/dc22-0239


How cells repair longevity-promoting 'recycling system'

 Today in Nature, University of Pittsburgh researchers describe for the first time a pathway by which cells repair damaged lysosomes, structures that contribute to longevity by recycling cellular trash. The findings are an important step towards understanding and treating age-related diseases driven by leaky lysosomes.

"Lysosome damage is a hallmark of aging and many diseases, particularly neurodegenerative disorders such as Alzheimer's," said lead author Jay Xiaojun Tan, Ph.D., assistant professor of cell biology at Pitt's School of Medicine and member of the Aging Institute, a partnership between Pitt and UPMC. "Our study identifies a series of steps that we believe is a universal mechanism for lysosomal repair, which we named the PITT pathway as a nod to the University of Pittsburgh."

As the cell's recycling system, lysosomes contain potent digestive enzymes that degrade molecular waste. These contents are walled off from damaging other parts of the cell with a membrane that acts like a chain link fence around a hazardous waste facility. Although breaks can occur in this fence, a healthy cell quickly repairs the damage. To learn more about this repair process, Tan teamed up with senior author Toren Finkel, M.D., Ph.D., director of the Aging Institute and distinguished professor of medicine at Pitt's School of Medicine.

First, Tan experimentally damaged lysosomes in lab-grown cells and then measured the proteins that arrived on the scene. He found that an enzyme called PI4K2A accumulated on damaged lysosomes within minutes and generated high levels of a signaling molecule called PtdIns4P.

"PtdIns4P is like a red flag. It tells the cell, 'Hey, we have a problem here,'" said Tan. "This alert system then recruits another group of proteins called ORPs."

ORP proteins work like tethers, Tan explained. One end of the protein binds to the PtdIns4P red flag on the lysosome, and the other end binds to the endoplasmic reticulum, the cellular structure involved in synthesis of proteins and lipids.

"The endoplasmic reticulum wraps around the lysosome like a blanket," added Finkel. "Normally, the endoplasmic reticulum and lysosomes barely touch each other, but once the lysosome was damaged, we found that they were embracing."

Through this embrace, cholesterol and a lipid called phosphatidylserine are shuttled to the lysosome and help patch up holes in the membrane fence.

Phosphatidylserine also activates a protein called ATG2, which acts like a bridge to transfer other lipids to the lysosome, the final membrane repair step in the newly described PITT -- or phosphoinositide-initiated membrane tethering and lipid transport -- pathway.

"What's beautiful about this system is that all of the components of the PITT pathway were known to exist, but they weren't known to interact in this sequence or for the function of lysosome repair," said Finkel. "I believe these findings are going to have many implications for normal aging and for age-related diseases."

The researchers suspect that in healthy people, small breaks in the lysosome membrane are quickly repaired through the PITT pathway. But if the damage is too extensive or the repair pathway is compromised -- due to age or disease -- leaky lysosomes accumulate. In Alzheimer's, leakage of tau fibrils from damaged lysosomes is a key step in progression of the disease.

When Tan deleted the gene encoding the first enzyme in the pathway, PI4K2A, he found that tau fibril spreading increased dramatically, suggesting that defects in the PITT pathway could contribute to Alzheimer's disease progression. In future work, the researchers plan to develop mouse models to understand whether the PITT pathway can protect mice from developing Alzheimer's disease.

This research was supported by the National Institutes of Health (P30AG024827, R01HL142663, R01HL142589, U54AG075931 and K01AG075142) and the UPMC Competitive Medical Research Fund.


Story Source:

Materials provided by University of PittsburghNote: Content may be edited for style and length.


Journal Reference:

  1. Jay Xiaojun Tan, Toren Finkel. A phosphoinositide signalling pathway mediates rapid lysosomal repairNature, 2022; DOI: 10.1038/s41586-022-05164-4

Exercise hormone halts Parkinson's disease symptoms in mouse study

 Researchers from Johns Hopkins Medicine and the Dana Farber Cancer Institute in Boston have shown that a hormone secreted into the blood during endurance, or aerobic, exercise reduces levels of a protein linked to Parkinson's disease and halts movement problems in mice.

Parkinson's disease, a neurologic condition that causes people to lose control over their muscles and movements, affects about 1 million people in the U.S.

If confirmed in additional laboratory research and clinical trials, the researchers' study in mice engineered to have Parkinson's disease symptoms could pave the way for a Parkinson's disease therapy based on the hormone irisin.

Results of the researchers' tests appeared Aug. 31 in Proceedings of the National Academy of Sciences.

Johns Hopkins Medicine's Ted Dawson, M.D., Ph.D., and Dana Farber's Bruce Spiegelman, Ph.D., worked together to look into the link between the exercise molecule irisin and Parkinson's disease.

For unknown reasons, endurance exercise has long been found to alleviate symptoms of Parkinson's disease. Dawson, whose research focuses on neurodegenerative diseases, including Parkinson's disease, said one of the first clues to the link between exercise, Parkinson's disease and irisin came from Spiegelman, whose first paper about irisin was published in 2012 in Nature and subsequently in other scientific journals, showing that a protein called an irisin peptide is released into the blood and increases with endurance exercise.

In the past decade, other laboratories have found that exercise elevates levels of irisin, and there is interest in looking into the connection between irisin and Alzheimer's disease as well as Parkinson's disease.

To test the effects of irisin on Parkinson's disease, Dawson and Spiegelman's teams began with a research model used by Dawson in which mouse brain cells are engineered to spread small, spindly fibers of alpha synuclein, a protein that regulates moods and movements related to the brain neurotransmitter dopamine.

When alpha synuclein proteins clump, those clusters kill dopamine-producing brain cells, a key trigger of Parkinson's disease. Fibrous clumps of alpha synuclein are very similar, says Dawson, to what is found in the brains of people with Parkinson's disease.

In the laboratory model, the researchers found that irisin prevented the accumulation of alpha synuclein clumps and its associated brain cell death.

Next, the research teams tested irisin's effects on mice engineered to have Parkinson's-like symptoms. They injected alpha synuclein into an area of the mouse brain, called the striatum, where dopamine-producing neurons extend. Two weeks later, the researchers injected a viral vector, which increased blood levels of irisin, which can cross the blood-brain barrier, into the mice. Six months later, mice that received irisin had no muscle movement deficits, while those injected with a placebo showed deficits in grip strength and their ability to descend a pole.

Additional studies of brain cells among the mice given irisin showed that the exercise hormone lowered levels of Parkinson's disease-related alpha synuclein between 50% and 80%. The research team demonstrated that irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.

"If irisin's utility pans out, we could envision it being developed into a gene or recombinant protein therapy," says Dawson, referring to the widening field of drug development aimed at using cellular genetics to treat disease. Dawson is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases, professor of neurology and director of the Johns Hopkins Institute for Cell Engineering.

"Given that irisin is a naturally produced peptide hormone and seems to have evolved to cross the blood brain-barrier, we think it is worth continuing to evaluate irisin as a potential therapy for Parkinson's and other forms of neurodegeneration" adds Spiegelman.

Dawson and Spiegelman have filed for patents on the use of irisin in Parkinson's disease. Spiegelman has created a biotechnology company, Aevum Therapeutics Inc., based in Boston, to develop irisin into treatments for neurodegenerative disease.

Other scientists who contributed to the research include Tae-In Kam, Hyejin Park, Shih-Ching Chou, Yu Ree Choi, Devanik Biswas, Justin Wang, Yu Shin, Alexis Loder, Senthilkumar Karuppagounder and Valina Dawson at Johns Hopkins, and Jonathan Van Vranken, Melanie Mittenbuhler, Hyeonwoo Kim, Mu A and Christiane Wrann at Harvard Medical School.

The research was funded by the JPB Foundation, the Maryland Stem Cell Research Fund, the Mark Foundation for Cancer Research, the Damon Runyon Cancer Research Foundation and Deutsche Forschungsgemeinschaft.


Story Source:

Materials provided by Johns Hopkins MedicineNote: Content may be edited for style and length.


Journal Reference:

  1. Tae-In Kam, Hyejin Park, Shih-Ching Chou, Jonathan G. Van Vranken, Melanie J. Mittenbühler, Hyeonwoo Kim, Mu A, Yu Ree Choi, Devanik Biswas, Justin Wang, Yu Shin, Alexis Loder, Senthilkumar S. Karuppagounder, Christiane D. Wrann, Valina L. Dawson, Bruce M. Spiegelman, Ted M. Dawson. Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisinProceedings of the National Academy of Sciences, 2022; 119 (36) DOI: 10.1073/pnas.2204835119

AbbVie Psoriatic Arthritis Drug Shows Long-term Effect On Skin, Joint Symptoms

 

  • AbbVie Inc 
    ABBV
     announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis. 
  • Results showed that at week 100 of the open-label extension period, patients receiving SKYRIZI reported improvement in skin and joint symptoms, with more than half of patients in KEEPsAKE 1 and 2 achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90). 
  • Additionally, the data demonstrated no new observed safety signals through 100 weeks.
  • At week 100, pooled results showed that 76% and 57% of patients, respectively, initially treated with Skyrizi, achieved resolution of dactylitis and enthesitis.
  • Skyriszi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

CVS, Amazon Deals Might Be Good for Patients, Bad for Primary Care

 Recent corporate deals to acquire primary care, home care, and value-based-care companies may not have much of an impact on primary care physicians in the near term, say observers. However, these large, well-resourced corporations such as Amazon and CVS may intend to scale up their acquired operations in ways that reduce the viability of independent primary care practices.

The two most eye-catching developments in the past month have been the announcement of Amazon's $3.9 billion deal to acquire concierge primary care company One Medical and CVS's agreement to buy Signify Health, a provider of technology-enabled in-home services. While the Amazon acquisition of One Medical is being scrutinized by the Federal Trade Commission (FTC), there's no indication that the FTC will challenge the buyout.

UnitedHealth recently struck a deal with Walmart to have its Optum subsidiary provide analytic and decision support that will help Walmart's burgeoning primary care clinics serve seniors under value-based contracts with Medicare Advantage plans.

All of these agreements emphasize the role of technology in making healthcare more efficient and consumer friendly. But observers point out there's more than that to high-quality healthcare.

"Of course, technology is important, but chronic care and especially end-of-life care require a human touch and not just someone who doesn't know you. So we can't forget that healthcare is not just about technology," Jonathan Weiner, PhD, professor of health policy and management at the Johns Hopkins Bloomberg School of Public Health, told Medscape Medical News.

Amazon Faces Stiff Challenge

One Medical currently has primary care clinics in 25 markets. Its business model is to give patients better access to doctors and provide more extensive services, including telehealth, in return for an annual fee that a Los Angeles Times article pegged at $199. Not surprisingly, most One Medical clinics are located in more affluent areas.

One Medical has recently lost a lot of money, and Amazon has offered to pay a high multiple of the firm's current stock price for ownership. So why is the technology giant so interested in a concierge primary care firm with a bleak financial prognosis?

According to the announcement of the merger agreement, Amazon wants to "reinvent" healthcare and likes One Medical's "human-centered and technology powered approach to healthcare." Amazon adds that it is guided by a "consumer obsession," which aligns with One Medical's approach to the patient experience.

But why primary care? "Amazon wants to get into primary care because they want to get into healthcare, and it's the base of the pyramid," Weiner said. He referred to Amazon's other investments in healthcare, including Amazon Care, a virtual and in-person primary care venture that it recently shuttered.

David Blumenthal, MD, president of the Commonwealth Fund, is less optimistic about Amazon's ability to reinvent healthcare by using One Medical as a wedge.

"I don't think you should assume this would happen easily or seamlessly or that ultimately they'd be successful in scaling One Medical," he said. "They do have money, they're risk takers, and they're good at technology — all of which is helpful — but ultimately they have to build networks in all the areas where they are working, which is very complicated and difficult to do, as insurance companies can tell you."

There's also very little money in primary care, Blumenthal noted. "Primary care is critical [to good outcomes], but the payoff to [owning] primary care comes from its ability to influence hospital and specialty services."

Therefore, he and a colleague maintained in a recent Harvard Business Review article that One Medical could become profitable only if it changed its business model to one focused on taking financial risk from health plans. While One Medical owns a primary care company called Iora that holds risk contracts with Medicare Advantage plans, Blumenthal believes it is more likely that One Medical itself would seek commercial risk contracts.

There's Profit in the Concierge Model

Andrew Bazemore, MD, senior vice president of research and policy for the American Board of Family Medicine, views Amazon's strategy differently. The concierge model, also known as "advance primary care," is catching on, he said, as middle-class people with jobs and health insurance become frustrated by the difficulty of obtaining medical appointments and procuring more than a few minutes of a doctor's time.

"If [Amazon/One Medical] can short circuit that with lesser wait times, longer visits, and better use of technology, you have a lot of inefficiencies that can be bypassed," he said.

On the other hand, he's concerned that if One Medical and other advance primary care operations continue to grow, they'll reduce access to primary care for people who can't afford their fees and will hurt traditional primary care practices.

"If you siphon off the healthier and wealthier patients and you don't get into the places where the most vulnerable patients with the greatest need for primary care are, this deal doesn't provide a boost, at least for that population," Bazemore said.

From the viewpoint of primary care offices, he noted, the problem is that concierge companies — along with urgent care centers, retail clinics, and third-party telehealth services — provide more convenient care for minor acute conditions that constitute the most lucrative cases for fee-for-service primary care physicians.

"The traditional practices will continue to take care of the sicker and often poorer patients with more complex medical needs," he said. Without the kinds of patients that One Medical caters to, however, these offices will find it increasingly difficult to stay in business, he noted.

Sidestepping HIPAA?

Another reason for Amazon to purchase One Medical, Bazemore suggested, is to use its patient data — as well as those of Iora — to target consumers with ads for health-related products that they can buy on Amazon's site. The Health Insurance Portability and Accountability Act (HIPAA) prohibits healthcare providers from sharing these data with third parties such as Amazon, and One Medical has stated that its patients' data will remain protected. Bazemore suggested Amazon may find ways to use its ownership of One Medical in marketing products.

"There are ways to ensure that, when patients enter a healthcare setting, they can be made aware of products that are available to them, even if not directly personalized, and that can lead to data sharing," he said.

Weiner agreed. "It's possible Amazon may try to rejigger things by offering a discount or a gym membership if the patient agrees to get special offers on health products," he said. "I'm sure they're looking for synergies."

CVS/Synergy Deal: Beyond Home Care

Although CVS also sells a variety of goods in its pharmacies, its strategy in acquiring Signify Health for $8 billion (after beating back a bid from Amazon) seems markedly different from that of Amazon.

CVS owns Aetna, one of the largest health insurers; it has a network of Minute Clinics in its drugstores; and it has built around 1000 HealthHub facilities that offer a wide range of nonemergency care. CVS has been closing some of its pharmacies, so it appears to be transforming itself into a diversified healthcare player.

Signify Health focuses on home care, mainly for Medicare Advantage plans and accountable care organizations (ACOs). It also owns Caravan, which provides infrastructure to ACOs for value-based contracting. Signify has more than 50 health plan clients, including CVS' Aetna division, and a network of 10,000 clinicians. These clinicians not only provide home care but also assess their patients' clinical and social needs and connect them with follow-up care and community-based resources.

Bazemore views CVS's acquisition of Signify as another advance primary care play. "CVS would tell you that Signify clinicians spend significantly more time with patients than they get in a typical primary care office visit. You can imagine that this competes with comprehensive primary care practices, whether their doctors are independent or employed by health systems."

It's not clear how many of these services would be provided by primary care physicians in their offices if firms such as Signify didn't exist. But there's no doubt that home care is taking a larger portion of the pie as the population ages, more patients are discharged to home after hospitalizations, and some health systems start to build hospital-at-home programs.

Blumenthal and Gretchen Jacobson, director of the Medicare program at the Commonwealth Fund, see other problems with operations such as Signify's. Said Jacobson, "One question that always comes up about home assessments is to what extent are they influencing and using care? Are they passed along to the primary care physician of the patient? Are they then used to get the resources and supports to the person that they may need? To the extent that they are actually used in that way, they can improve the quality of care."

However, Medicare Advantage plans that use home assessments don't necessarily pass them on to primary care doctors, she said.

Blumenthal added that this information should also be communicated to specialists who are managing chronic conditions.

"The home assessment could be very useful, but it has to flow out along the many pathways of the healthcare system and get integrated into the workflow of a fragmented system with very distorted incentives," he said.

https://www.medscape.com/viewarticle/980561

Siemens Healthineers' Corindus surgical robot clears brain aneurysm study

 Siemens Healthineers’ Corindus division has put forward what it describes as a first-of-its-kind clinical study of the use of a surgical robot to help seal off an aneurysm within the brain.

According to the company, the CorPath GRX Neurovascular System successfully completed 94% of its robotic-assisted endovascular procedures without the surgeon having to switch to a manual approach during the operation.

The device includes a precise, remote-controlled machine that can steer a microcatheter through the blood vessels of the leg and up into the brain during live imaging procedures. After reaching the aneurysm, where the side of an artery has ballooned out and is at risk of rupturing, the device can feed coils of material into the pocket to help stem the blood flow and relieve the pressure.

More than 64% of patients saw the complete obliteration of their aneurysms, and 78% showed no clinical symptoms following the procedure. The remaining 22% were rated as a 1 or 2 on the Modified Rankin Scale for Neurologic Disability, the company said in its release, meaning they were able to continue to care for themselves without assistance and could continue most daily activities.

At the same time, the noninferiority study met its safety goals in 95.7% of cases, defined as avoiding blood vessel damage or ruptures, or any subsequent blood clotting events within the 24 hours following the procedure or the patient’s discharge from the hospital.

“Neurovascular intervention demands extreme precision to achieve optimal clinical outcomes,” the study’s principal investigator, Michel Piotin, M.D., Ph.D., head of interventional neuroradiology at the Rothschild Foundation Hospital in Paris, said in Siemens’ release. “The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels.”

The study results were presented at the European Society of Minimally Invasive Neurological Therapy Congress in Nice, France. It included 117 patients from 10 clinical sites in six different countries, representing a range of different aneurysm sizes, locations and characteristics.

The CorPath GRX previously received FDA and European approvals for percutaneous coronary interventions and other cardiovascular procedures. It has also received a CE mark for brain procedures; currently, Siemens is aiming to add more regulatory clearances for neurovascular indications.

“By incorporating robotic platforms in this space, we are paving the way for remote interventional procedures in the future that will connect patients to specialized interventionalists for treatment, regardless of location,” Raymond Turner, M.D., chief medical officer of neuroendovascular efforts at Corindus, said in the release.

https://www.fiercebiotech.com/medtech/siemens-healthineers-corindus-surgical-robot-clears-brain-aneurysm-study